Next-generation, selective kinase medicines

Our proprietary scientific platform enables us to rapidly and reproducibly design medicines that selectively target kinase drivers of disease, enabling improved potency, less off-target activity and an increased probability of clinical success.

Blueprint Medicines’ pralsetinib, an investigational RET inhibitor for advanced non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other RET-altered solid tumors

Cometriq® (cabozantinib), an FDA-approved multi-kinase inhibitor for advanced MTC

Caprelsa® (vandetanib), an FDA-approved multi-kinase inhibitor for advanced MTC

Kinome illustrations reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

A focused strategy

Our research focuses on kinase targets where we believe our technology can lead to meaningful improvements in treatment.


Well-recognized kinases that are difficult to target with existing technologies


Mutant kinases that have become resistant to current treatments

Novel biology

New targets identified with our computational and cell biology expertise